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This case example refers to a patient who developed ED after the 
diagnosis of CAD has been made representing the classic “exception 
to the rule” of the ASH. We discuss the potential pathophysiologic 
background that may explain what we may call the “CAD-ED-CAD 
sequence” and how it may still fit the ASH.
CASE EXAMPLE
A 54-year-old man was admitted to the emergency room of our hospital 
because of chest pain lasting more than 12  h. His cardiovascular 
history was unremarkable, except for borderline hypertension and 
hypercholesterolemia  (both untreated) and sedentary lifestyle. 
The electrocardiogram on admission showed anterior myocardial 
infarction (AMI). Coronary angiography was immediately performed, and an 
occluded proximal left anterior descending artery was detected (single-vessel 
disease). Primary percutaneous coronary intervention  (PCI)  (two 
drug-eluting-stents [DESs] implanted) was performed with good vessel 
recanalization (Figure 1a). The post-PCI period was uneventful. A moderate 
left ventricular dysfunction (ejection fraction [EF] 45%, normal value >55%) 
was detected by echocardiogram. The patient was discharged on the 6th day 
on double antiplatelet treatment (aspirin 100 mg per day + clopidogrel 75 mg 
per day), beta-blocker (atenolol 50 mg per day), angiotensin-converting 
enzyme inhibitor (ramipril 5 mg per day) and statin (atorvastatin 40 mg) 
(all type I, a medication according to European Society of Cardiology 
guidelines). A questionnaire for ED (International Index of Erectile Function 
5 [IIEF-5]) was given to the patient in the 3rd post-PCI day and found to be 
normal (score: 23, normal value ≥23).
INTRODUCTION
Erectile dysfunction  (ED) is defined as the inability to reach and 
maintain an erection to successfully perform sexual intercourse. The 
condition is present in up to 30 million men in the United States and 
approximately 100 million worldwide.1 In the Massachusetts Male 
Aging Study, 34.8% of men aged 40–60 years had moderate-to-complete 
ED and 15% of men aged 70 had complete ED.2 The risk of ED was 
directly influenced by age, number of risk factors and presence of 
cardiovascular diseases (CVDs).2,3 Particularly, a high prevalence of 
ED has been reported in conjunction with common vascular diseases, 
included coronary artery disease (CAD).4–9
We proposed a pathophysiological mechanism, called the “artery 
size” hypothesis (ASH),10,11 to explain the link between ED and CAD. 
Given the systemic nature of atherosclerosis, all major vascular beds 
should be affected to the same extent. However, symptoms at different 
points in the system rarely become evident at the same time. This is 
likely the result of larger vessels being able to better tolerate the same 
amount of plaque when compared with smaller ones. If true, men 
with early stage ED will rarely have concomitant CAD (ED as an early 
marker of CAD). When atherosclerosis significantly affects coronary 
circulation, however, the penile artery will be even more damaged, 
accounting for the coexistence of sexual and anginal symptoms. Thus, 
ED and CAD should be considered as two different aspects of the same 
disease, ED should come first before CAD, and CAD patients should 
frequently complain of ED. However, this is not always the case.
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Early follow‑up
The patient was reassessed at a 6 months follow-up and found to be 
asymptomatic. He underwent a stress myocardial scintigraphy (during 
beta-blocker “wash-out”) that turned out to be negative for inducible 
ischemia and a trans-thoracic echocardiogram that showed 
improvement (EF: 61%) of left ventricular function. Blood pressure was 
well under control, whereas cholesterol-low-density lipoprotein (LDL) 
level was still suboptimal (110 mg dl−1). At that time, he first complained 
of ED with an IIEF-5 score of 19. Thus, according to the favorable 
cardiologic results and to the potential drug-induced ED, beta-blocker 
was withdrawn. Atorvastatin was increased (up to 80 mg day−1) and a 
regimen of physical activity (at least 30 min day−1 of aerobic exercise) 
was prescribed. The patient was anyway commenced on sildenafil 
50 mg on demand for ED treatment.
Late follow‑up
At 15 months follow-up ED became moderate (IIEF-5 questionnaire 
score: 17) and the patient complained of chest pain associated with 
“unrevealing” stress test response. Cholesterol-LDL level was below 
100 mg dl−1. Treatment with beta-blocker was restarted while PDE-5 
inhibitor was withdrawn. A  second-level noninvasive test was 
prescribed to better assess patient coronary reserve, but was refused. At 
23 months follow-up, exercise stress test showed significant ST-segment 
changes involving the antero-lateral leads associated with angina 
pectoris. ED was now severe (IIEF-5 score: 10). Coronary angiography 
was performed. While a wide stents patency on the anterior descendent 
artery was detected, a severe (90% diameter stenosis), de‑novo lesion 
involving the middle right coronary artery was found that was fixed 
with PCI and one DES (Figure 1b).
DISCUSSION
The patient cardiac history began with an AMI as the first clinical 
manifestation of CAD. According to the ASH, some degree of sexual 
dysfunction would have been expected in this “newly diagnosed” 
cardiac patient. However, this was not the case as shown by a normal 
score  (≥23) of the standard self-administered IIEF questionnaire. 
This apparent contradiction may be explained by the different 
pathophysiologic background subtending acute versus chronic 
coronary syndromes (CCS). Acute myocardial infarction is the typical 
acute coronary syndrome (ACS) and is the first clinical manifestation of 
CAD in 80% of the cases. The remaining 20% of patients develope AMI 
in the setting of chronic CAD. The mechanism subtending AMI is an 
abrupt thrombotic coronary occlusion superimposed on a preexisting, 
noncritical  (<50% diameter narrowing) stenosis in an otherwise 
angiographically normal coronary tree (single-vessel disease or mild 
coronary atherosclerosis pattern). The lack of preexisting significant 
coronary stenosis accounts for the absence of coronary symptoms until 
the acute event occurs. Since atherosclerosis is a systemic disorder, one 
can speculate that a similarly mild vascular involvement is present also 
at the level of hypogastric/pudendal circulation. If true, the rate of ED 
should be low in patients with AMI and single-vessel disease (Figure 2). 
In contrast to AMI, patients with CCS usually showed a severe, 
diffuse coronary artery involvement with long-standing anginal 
symptoms. Once again it can be speculated that a similarly severe 
vascular involvement is present also at the level of hypogastric/
pudendal circulation accounting for a high rate of ED in this type of 
CAD. In the AssoCiatiOn Between eRectile dysfunction and coronary 
Artery disease  (COBRA) trial12 we tested this hypothesis in 385 
consecutive patients with a first diagnosis of CAD with different clinical 
presentation (ACS vs CCS) and the extent of vessel involvement (1 vs 
2–3 vessel disease) by coronary angiography. Patients were divided 
into four groups: ACS with 1-vessel disease (group 1), ACS with 2–3 
vessel disease (group 2), CCS (regardless the number of vessel involved, 
group 3) and subjects with suspected CAD but ultimately found to 
have entirely normal coronary anatomy (NCA group). The overall ED 
prevalence was 47%. When separately considered, ED rate was 22%, 
55% and 65% in groups 1, 2 and 3, respectively (P = 0.0001 groups 1 vs 
2 and 3 and P = NS groups 2 vs 3). The NCA group had an ED rate of 
24% (P = NS vs group 1 and P < 0.0001 vs groups 2 and 3). ED difference 
was paralleled by difference in atherosclerotic burden  (assessed by 
the Gensini’s score) with group 1 having significantly less extent of 
CAD as compared to groups 2 and 3. In logistic regression analysis, 
Figure 1: Coronary angiography at the time of anterior myocardial infarction (left 
panel) and a 24 months follow-up (right panel). The left coronary artery is shown 
in the upper part of both panels whereas the right coronary artery in shown in 
the lower part. In the 2005 coronary angiography a thrombotic occlusion of 
the left anterior descending artery is marked by the white arrow (in the frame 
the angiographic result after 2 drug-eluting-stents [DES] implantations). In the 
2007 coronary angiography a wide stent patency is shown, whereas a critical 
stenosis on the middle right coronary artery is marked by the black arrow (in 
the frame the angiographic result after 1 DES implantation).
Figure 2: A graphic depiction of the artery size hypothesis in a patient 
with acute myocardial infarction. In most of patients, acute myocardial 
infarction (AMI) is due to abrupt coronary occlusion superimposing on isolated, 
nonsignificant coronary lesion. In other terms, AMI occurs in a modestly 
involved coronary tree. Penile circulation might be supposed to be similarly 
mild involved, accounting for low erectile dysfunction prevalence. CAD: 
coronary artery disease; CVD: cardiovascular disease; ED: erectile dysfunction.
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age, multi-vessel versus single-vessel disease and CCS versus ACS was 
independent predictors of ED. Thus, the results of the COBRA trial 
confirmed the working hypothesis by showing a low ED rate in ACS 
with 1 vessel disease (similar to ED rate in normal subjects) and a high 
ED rate in CCS with multi-vessel disease. The group of patients with 
ACS and multi-vessel disease deserves some additional comments. 
Although this group clinical presentation was similar to group 1-that 
is, AMI - the coexisting diffuse coronary artery involvement detected 
by angiography likely accounted for an ED rate  (55% vs 22%, 
P < 0.0001) and Gensini’s score significantly higher than group 1 and 
similar to group 3. Thus, as far as ED rate is concerned, the “favorable 
pathophysiologic” background of group 1 patients was offset by the 
advanced (silent) atherosclerosis involvement. We confirmed the initial 
COBRA trial results in a widen patient population of 705 consecutive 
patients with CAD (Figure 3). No difference in ED rate was found 
between patients with NCA and group  1. Group  2  patients had a 
RR of ED of 2.6  (confidence interval  [CI]: 1.53–4.35, P  =  0.0004) 
versus normals and 2.9  (CI: 1.82–4.8, P  <  0.0001) versus group  1, 
after adjustment for age, body mass index, number of risk factors 
and diabetes. These numbers confirm the role of the type of clinical 
presentation as a major determinant of the overall ED rate in CAD 
patients. Thus, the wide range of ED rate in previous studies (45%–75%) 
is the result of many factors, including patient population heterogeneity, 
differences in ED and CAD diagnosis and inclusion/exclusion criteria 
and absence of data of clinical presentation and CAD extension.
The early follow-up of this patient was characterized by the onset of 
ED at 6 months (ED after CAD). Potential reasons include psychological 
factors, drug-induced ED and progression of vascular atherosclerosis. 
A significant number of patients have been reported to develop sexual 
dysfunction within 3–6 months following a diagnosis of CVD (angina, 
AMI, congestive heart failure  [CHF], arrhythmias) or cardiac 
procedures (coronary artery bypass graft, percutaneous transluminal 
coronary angioplasty, automatic implantable cardioverter defibrillator, 
cardiac transplant).13 While 25% returned to the previous level of sexual 
activity, 50% had reduced the number of intercourse/month, and 25% 
do not resume sexual activity at all. Pooling data from five previous 
studies,14–18 a common issue in subjects who were sexually active before 
the cardiac event was a reduction of both frequency and satisfaction with 
sexual activity (Figure 4). Although development of true ED has been 
reported in up to 40% of cases, the heterogeneity of patient population 
characteristics and definition/diagnosis of sexual dysfunction/ED, 
the lack of systematic data on precardiac event sexual status and 
and/or postcardiac event condition/medications significantly hamper the 
interpretation of these results. Psychological factors play an important 
role in this trend. Among those who showed reduction/cessation 
of sexual activity, the reasons more frequently reported were fear of 
coital death or repeated AMI  (involving both patient and partner), 
performance anxiety, loss of libido  (changes in sexual desire) and 
depression or guilty feelings.13,19 This behavior was mainly the result 
of lack of knowledge of the disease, need of cardiac rehabilitation and 
counseling and ignorance of the cardiac risk of sexual activity. In a recent 
multisite observational study of sexual-related outcomes after AMI in 
1879 patients  (the TRIUMPH registry) the absence of counseling at 
hospital discharge about when to resume sexual activity was a significant 
predictor of loss of activity at 1 year follow-up for both sexes.20
Drugs used for treatment of CVDs have often been accused of 
influencing erectile function. While evidence at best is firm only for 
thiazide diuretics, the use of beta-blockers has been found to have 
neutral or detrimental effects on sexual function.21 A decreased 
perfusion pressure due to unopposed a-receptor stimulation  (not 
experimentally proven or clinically investigated) and an attenuated 
release of sex hormones and depression of Leydig cell activity secondary 
to sympathetic nervous system suppression have been suggested to be 
involved in the reduction of sexual function.22,23 The provocative paper 
by Silvestri et al.24 tested the effect on sexual function of a 3 months 
course of atenolol 50 mg per day in three groups of patients who were 
blinded, knew the drug but not side-effects and knew both drug and 
side-effects, respectively. Interestingly, ED rate was significantly higher 
in those who knew the drug side-effects when compared to those 
without knowledge (31% vs 3%, P < 0.01). Moreover, patients with 
new ED entered a second phase of the study being treated with either 
placebo or sildenafil. ED improved in all but one case regardless the 
treatment confirming the role of knowing drug side-effects. If treatment 
with beta-blockers is clinically necessary for a CAD patient, nebivolol 
should be preferred. This third-generation beta-blocker has been found 
to own nitric-oxide-mediated vasodilator properties that answer for 
a neutral or even an improvement in sexual function.25–28 In general, 
unless ED developed within 4 weeks of initiating therapy with any 
cardiovascular drugs, there is little evidence to support switching the 
suspect drug to alleviate symptoms of sexual dysfunction.
Finally, progression of cavernous (and coronary) atherosclerosis 
may be an alternative cause of ED after a coronary event especially if 
it lasts and/or worsens over time despite appropriate treatment of both 
psychologic and pharmacologic influences. In this occurrence, ED 
might represent a late warning sign of a flow-limiting coronary stenosis. 
The actual prevalence of ED after CAD is largely unknown. Available 
Figure 3: Erectile dysfunction (ED) prevalence in 705 consecutive patients with 
anterior myocardial infarction and 1 or 2–3VD, chronic coronary syndromes 
and normal coronary anatomy. AMI: anterior myocardial infarction; CCS: 
chronic coronary syndromes; RR: relative risk; NCA: normal coronary anatomy; 
NS: not significant; VD: vessel disease.
Figure 4: Number of intercourses (times per month) in five previous studies. 
For each study the left column represent the precardiac event number 
of intercourses and the right column the postcardiac event number of 
intercourses.
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information came from the Thompson’s study.29 The authors examined 
the association between ED and subsequent CVD in 9457 men 
enrolled in the placebo-arm of the Prostate Cancer Prevention Trial. 
Among 4247 men without ED at study entry, incident ED (defined as 
the first report of ED of any grade) developed in 57% after 5 years of 
follow-up and was associated with a significant higher rate of AMI/
angina when compared to men without ED. Overall, among 486 
cardiovascular events  (i.e.  AMI, angina, transient ischemic attack, 
CHF, fatal/nonfatal cardiac arrest, arrhythmias), 67% involved the 
coronary circulation (angina and/or AMI) and occurred in roughly 
half of the cases after ED diagnosis (ED prior to CAD). In patients with 
normal sexual function who had a cardiac event, ED either followed 
or never occurred in 55% and 45% of cases, respectively (Figure 5). 
Unfortunately, in those who actually develop ED after CAD, the lack 
of data about psychological, pharmacological and other potential 
influences hampers the interpretation of the reasons for the reverse 
temporal sequence. We do think that ASH may still explain this 
occurrence. In-fact, a progression of atherosclerosis will likely affect 
first the smaller artery (penile circulation) leading to new ED onset 
despite negative cardiological tests of inducible ischemia (Figure 6). 
Later in the follow-up, any further plaque growing will significantly 
reduce coronary lumen diameter accounting for both angina symptoms 
and ECG changes of ischemia during the stress tests. At this time, 
coronary angiography may show new lesions (Figure 7). If this holds 
true, ED developing late after a cardiac event may represent an “early 
sign” of vascular disease progression in patients with known CAD with 
a similar pathophysiologic mechanism as in the case of ED prior to 
CAD. We do not have data about the average time interval between ED 
and “new angina” (18 months in this specific patient). As for ED prior to 
CAD, the length of this time interval is the result of a balance between 
adverse (i.e. age, risk factor profile, duration of ED at the time of the 
first diagnosis) and protective factors (i.e. regular exercise program, 
appropriate diet and pharmacological treatment of risk factors). 
Whatever the length of this interval is, new onset ED should rise the 
suspicion of CAD progression, providing a window of opportunity for 
an aggressive risk reduction management in these patients.
Although initial clinical data appear to support the “ASH,” exceptions 
may be found in the every-day clinical practice. This is due to the fact 
that this hypothesis besides on the conceptual model that exposure to 
common risk factors leads sequentially and uniformly across all vascular 
beds to endothelial dysfunction followed by intima-media thickening 
and lately, by vascular obstruction and flow-limiting stenoses. The 
well-known notion that upper limbs arteries are less affected by 
atherosclerosis as compared to lower limbs arteries suggests that the 
development of vascular disease is the result of a complex interplay 
of genetic, environmental, biochemical and mechanical factors. Thus, 
atherosclerosis might become clinically evident in some individual, but 
not in others despite a similar risk factor profile and in a given subject, 
vascular obstruction may involve a larger artery while sparing a smaller 
one.30,31 Finally, unfavorable endothelial and inflammatory state has 
been found to play an additional role on top of angiographic coronary 
involvement in the determination of ED in patients with different types 
of CAD.32,33 Thus, the “ASH” should be considered a putative mechanism 
to explain the relationship between ED and CAD.
CONCLUSIONS
This case report study depicts the less know clinical scenario of ED 
developing after a cardiac event. We think that this case may still fit 
the pathophysiological mechanism of the ASH.
Figure 5: Number of major adverse cardiac and cerebrovascular events along 
the 5 years follow-up in the Thompson’s study. AMI: anterior myocardial 
infarction; CHF: congestive heart failure; CV: cardiovascular; ED: erectile 
dysfunction ; TIA: transient ischemic attack.
Figure 6: A graphic depiction of the artery size hypothesis in a patient (as 
in Figure 2) with acute myocardial infarction at a 6 months follow-up time 
interval when erectile dysfunction developed. Progression of atherosclerosis 
led to a significant stenosis at the level of penile circulation. The same 
plaque burden was accommodated in larger arteries (right and left 
circumflex coronary arteries) without inducing flow-limiting stenosis. 
CAD: coronary artery disease; CVD: cardiovascular disease; ED: erectile 
dysfunction.
Figure 7: A graphic depiction of the artery size hypothesis in a patient 
(as in Figure 2) with acute myocardial infarction at a 23 months follow-up 
time interval when angina pectoris associated with positive ST changes 
during exercise developed. Progression of atherosclerosis now significantly 
involved both penile and right coronary arteries. CAD: coronary artery disease; 
CVD: cardiovascular disease; ED: erectile dysfunction.
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